Division of Bone Marrow Transplantation, Department of Hematology/Oncology, St. Jude Children's Research Hospital and Departments of Pediatrics and Medicine, University of Tennessee College of Medicine, Memphis, Tennessee, USA.
Leuk Lymphoma. 1991;5(2-3):77-83. doi: 10.3109/10428199109068109.
As evidence has accumulated that allogeneic bone marrow transplantation provides therapeutic benefit by means of a graft versus malignancy effect, there has been a corresponding increase in interest in inducing or enhancing such an effect after chemotherapy and/or autologous bone marrow transplantation. Administration of Interleukin-2 may be one way of achieving this aim. Recent studies have shown the cytokine is tolerated after ABMT/chemotherapy in immunomodulatory doses and that the MHC unrestricted cytotoxic effector mechanisms induced can indeed discriminate between normal and malignant tissue. As always, larger scale randomized studies will be required before the therapeutic efficacy of this approach can been assessed.
随着越来越多的证据表明异基因骨髓移植通过移植物抗恶性肿瘤效应提供治疗益处，人们对在化疗和/或自体骨髓移植后诱导或增强这种效应的兴趣也相应增加。白细胞介素-2的应用可能是实现这一目标的一种方法。最近的研究表明，细胞因子在 ABMT/化疗后的免疫调节剂量下是可以耐受的，并且诱导的 MHC 非限制性细胞毒性效应机制确实可以区分正常组织和恶性组织。与以往一样，在评估这种方法的治疗效果之前，还需要进行更大规模的随机研究。
